Corient Private Wealth LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,233 shares of the medical research company's stock after selling 7,986 shares during the period. Corient Private Wealth LLC's holdings in IQVIA were worth $2,601,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the business. Private Trust Co. NA lifted its position in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after acquiring an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co raised its stake in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. lifted its holdings in shares of IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after buying an additional 56 shares during the last quarter. Finally, Cypress Wealth Services LLC increased its stake in IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after buying an additional 57 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.
IQVIA Price Performance
Shares of NYSE:IQV traded down $1.48 on Wednesday, hitting $179.91. The company had a trading volume of 1,316,674 shares, compared to its average volume of 1,244,048. The company has a market cap of $31.72 billion, a PE ratio of 23.99, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average of $193.92 and a 200 day moving average of $207.10. IQVIA Holdings Inc. has a 52-week low of $179.16 and a 52-week high of $253.84. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on IQV. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Truist Financial reissued a "buy" rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.
Read Our Latest Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
